Please login to the form below

Not currently logged in
Email:
Password:

LAMA/LABA

This page shows the latest LAMA/LABA news and features for those working in and with pharma, biotech and healthcare.

GSK files first application for triple COPD therapy

GSK files first application for triple COPD therapy

The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... GSK's head of

Latest news

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... LAMA, LABA and

  • Boehringer COPD drug 'could give patients more independence' Boehringer COPD drug 'could give patients more independence'

    Boehringer needs Spiolto to hit the ground running as its faces increasing competition in the COPD market, with a number of other LAMA/LABA combinations jostling for elbow room in the

  • Novartis sales dip, but all eyes are on Entresto Novartis sales dip, but all eyes are on Entresto

    In its respiratory portfolio, Novartis said long-acting muscarinic antagonist/long-acting beta agonist (LAMA/LABA) product Ultibro (indacaterol and glycopyrronium bromide) added $66m to its coffers, three times the sales ... Pharma chief David Epstein

  • Boehringer's Spiriva combo approved in first EU markets Boehringer's Spiriva combo approved in first EU markets

    Called Spiolto, the new drug combines the active ingredient in Spiriva - long-acting muscarinic antagonist (LAMA) tiotropium - with the long-acting beta agonist (LABA) olodaterol, the active ingredient in the ... Since then, approval of new LAMA/LABA

  • Boehringer bags FDA approval for Spiriva-based combo Boehringer bags FDA approval for Spiriva-based combo

    shifts towards LAMA/LABA combination therapy and is due to lose patent protection in the US in 2018. ... Stiolto is being positioned as a successor to Spiriva, and is the second LAMA/LABA combination to reach the US market after GlaxoSmithKline's Anoro

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics